Back To: Home : Featured Technology : Stem Cell

CLICK HERE FOR WHAT'S NEW IN:
 

Capital alliance formed to discuss iPS collaboration
May 2013
SHARING OPTIONS:

TOKYO—An agreement has been signed between Retina Institute Japan K.K. (RIJ) and Dainippon Sumitomo Pharma Co. Ltd. (DSP) regarding a DSP investment into RIJ. Per the terms of the agreement, DSP has subscribed for 1.5 billion yen of third-party allocation of shares by RIJ, and will exclusively discuss with RIJ the possibility of collaborating in and outside of Japan on induced pluripotent stem cell technology as a cure for age-related macular degeneration, a leading cause of blindness.
 
"The significance of this development cannot be underestimated," Dr. Hardy T. S. Kagimoto, president of RIJ, said in a press release. "It is a privilege for RIJ to have the opportunity to commercialize this exciting new technology and to transform the lives of millions of patients globally."

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.